Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities
Germany has launched the European Union's first compassionate use program for psilocybin, allowing patients access to the treatment at two specialized centers. Researchers are currently working on securing insurance coverage and managing patient interest while navigating the rigid structure of public hospitals.
Why it matters
This represents a significant shift in European drug policy and medical research regarding the therapeutic use of psychedelics.
Last summer, Germany’s medicines regulator quietly green-lit a psilocybin compassionate use program, the first such pathway in the European Union (see Germany Establishes EU’s First Psilocybin Compassionate Access Program ). Two centres are permitted to offer psilocybin dosing at present: OVID Clinic Berlin, a private clinic in the nation’s capital, and the Central Institute of Mental Health (CIMH) in Mannheim, a public hospital.
The article provides a factual overview of a medical program and interviews with the practitioners involved.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in